Company

About Us

Astrego is a rapidly growing in vitro diagnostic company based in Uppsala, Sweden. After a decade of fundamental research, the company was founded in March 2017 with the mission to help in the global fight against antimicrobial resistance (AMR).

The company name comes from Antibiotic Susceptibility Testing – AST, and rego – being latin for guide, steer or manage. Our products are designed to guide physicians in the selection of effective antibiotic treatments to improve patient outcomes and make antibiotic stewardship easy.

Our team combines multidisciplinary scientific excellence with seasoned entrepreneurs and diagnostic industry management.

About Us

Astrego is founded on technology originally developed for fundamental research on bacterial growth at the level of single cells (1) and sensitive bacterial imaging (2,3). It was however realized that this technology, in its simplest form, also had the potential to be used for very fast antibiotic susceptibility testing (4).

In Astrego this mission has been taken on by a dedicated team of experienced engineers with the necessary competences to transform this unique technology into diagnostic products that will be disruptive for clinical microbiology and make antibiotic stewardship easy.

1. Wallden et al. Cell 20172. Hammar et al. Science 20123. Hammar et al. Nature Genetics 2014, 4. Baltekin et al. PNAS 2017

About Us

Astrego is founded on technology originally developed for fundamental research on bacterial growth at the level of single cells (1) and sensitive bacterial imaging (2,3). It was however realized that this technology, in its simplest form, also had the potential to be used for very fast antibiotic susceptibility testing (4).

In Astrego this mission has been taken on by a dedicated team of experienced engineers with the necessary competences to transform this unique technology into diagnostic products that will be disruptive for clinical microbiology and make antibiotic stewardship easy.

1. Wallden et al. Cell 20172. Hammar et al. Science 20123. Hammar et al. Nature Genetics 2014, 4. Baltekin et al. PNAS 2017

News

  • Astrego is accelerating product development activities in Uppsala. Open positions.
    2020-01-29
  • Sysmex Invests in Astrego Diagnostics. Read Press Release here.
    2020-01-29
  • Astrego and University of Oxford presented the EITH-funded joint project at the EITH summit in Paris.
    2019-12-02/03
  • Astrego participated in the Diagnostic Tool Development Workshop  organized by MORU Tropical Health Network in Bangkok.
    2019-11-25/26
  • Astrego’s patent (JP 6600349) is now also granted in Japan.
    2019-10-11
  • Astrego’s core patent (EP 3167044) is now also granted in Europe.
    2019-10-09
  • Astrego presented Captiver and discussed primary care adoption with 20 dedicated scientists and medical doctors at the AIMday on Antimicrobial Resistance organized by the University of Oxford.
    2019-07-04
  • The EIT-health funded collaboration project with University of Oxford, Region Uppsala and Public Health Wales was kicked-off. The aim of this project is to evaluate the use of Captiver system in primary care settings for UTI-diagnostics with direct AST.
    2019-07-03
  • A study evaluating Astrego’s Captiver System for phenotypic AST within 30 minutes directly from positive blood cultures was presented at ECCMID 2019. The poster presents the result of the study conducted at Karolinska University Hospital with prospectively collected positive blood cultures from patients with blood stream infections.
    2019-04-16
  • Astrego won the pitch competition at the 12th Berlin Conference on Life Sciences “Novel Antimicrobials and AMR Diagnostics 2019”.
    2019-03-15
  • Astrego’s patent (EP 3167061) is now granted in Europe.
    2019-02-20
  • Astrego receives SEK 1.67 million from Medtech4Health for a collaboration project with the Dept. of Laboratory Medicine at Karolinska Hospital, Stockholm, Sweden. The project aims to evaluate the use of the Astrego technology to perform rapid AST on blood stream infections.
    2018-11-16
  • The PNAS paper describing the Astrego technology is extensively discussed in the latest issue of the ASM Podcast: “This Week in Microbiology”.
    2018-08-09
  • Astrego has been granted a US patent on the core technology (U.S. pat.no. 10,041,104).
    2018-08-07

News Archive

  • Astrego presents at “The 14th International Congress of the European Association for Veterinary Pharmacology and Toxicology 2018”, Wroclaw, Poland.
    2018-06-25
  • Astrego receives SEK 1 million to support clinical evaluation of the qUTI-system in collaboration with the Dept. of Infectious Disease at Akademiska University Hospital, Uppsala, Sweden. The grant is given within the call “Projekt för bättre hälsa” funded by Medtech4Health and the Swelife program.
    2018-05-18
  • 77Elektronika deliver first industrialized prototypes of the qUTI instrument. 2018-02-18
  • Astrego presents at the AACC Conference “Emerging Clinical & Laboratory Diagnostics in the Healthcare Ecosysytem”, San Diego, USA. 2017-10-31
  • Professor Elf is interviewed in The Pathologist about Astrego´s technology. December 2017
  • Astrego’s core paper is reviewed in JAMA. 2017-10-10
  • Astrego´s core paper is selected as the Editor´s choice in Science Translational Medicine. 2017-09-06
  • Astrego & 77Elektronika Kft enter collaboration for development of the qUTI instrument. 77Elektronika is a Hungarian-based market leading manufacturer of in vitro diagnostic urine analysis and urine sediment devices. 2017-08-25
  • Astrego´s core paper is published in PNAS. 2017-08-08
  • Astrego receive a “Seal of Excellence”from the H2020 SME Instrument for our Phase 1 application and SEK 0.5 million from Vinnova to perform market studies and prepare a business plan for the qUTI system. 2017-05-03
  • Astrego Diagnostics AB is founded by management and a team of independent investors 2017-03-28

Management

Ove Öhman, CEO

Özden Baltekin, CSO

Mike Read PhD, COO

Mikael Olsson, CTO

Petter Hammar, Director Assay R&D

    Board

    Sven Holmlund, Chairman

    • Business leader & independent investor

    Johan Elf

    • Technology inventor & Scientific front-runner

    Ernst Westman

    • IVD entrepreneur & Independent investor

    Johan Winnerblad

    • Top-ranked M&A lawyer

    Location

    Astrego Diagnostics is located in Uppsala Sweden, a city with long history of fostering successful collaboration between Uppsala University and the local Bio- and Medtech industry. Success stories include Pharmacia (now GE Healthcare and Pfizer), Biacore (part of GE Healthcare), Phadia (part of Thermo Fisher), Åmic (now part of J&J), Q-med (now Galderma) and Pyrosequencing (out licensing to Illumina).

    Contact

    Ove Öhman, CEO

    Email

    info@astrego.se

    Adress

    Vallvägen 4B
    SE-756 51 UPPSALA
    Sweden